Rachael C. Natrajan

Dr. Rachael C. Natrajan

The Institute of Cancer Research (ICR)
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2008 in Nature
Verified
Journal Article
Closed access
PDF file
Stacey EdwardsStacey Edwards
Stacey Edwards
RBRachel Brough
Rachel Brough
CLChristopher J. Lord
Christopher J. Lord
RNRachael C. Natrajan
Rachael C. Natrajan
RVRadost Vatcheva
Radost Vatcheva
AAAlan Ashworth
Alan Ashworth

24 December 2009 in Nature
Verified
Journal Article
Open access
PDF file
PSPhilip J. Stephens
Philip J. Stephens
DMDavid J. McBride
David J. McBride
MLMeng-Lay Lin
Meng-Lay Lin
IVIgnacio Varela
Ignacio Varela
EPErin D. Pleasance
Erin D. Pleasance
MSMichael R. Stratton
Michael R. Stratton
Multiple somatic rearrangements are often found in cancer genomes; however, the underlying processes of rearrangement and their contribution to cancer development are poorly characterized. Here we use a paired-end sequencing strategy to identify somatic rearrangements in breast cancer genomes. There are more rearrangements in some breast cancers than previously appreciated. Rearrangements are more frequent over gene footprints and most are intrachromosomal. Multiple rearrangement architectures are present, but tandem duplications are particularly common in some cancers, perhaps reflecting a specific defect in DNA maintenance. Short overlapping sequences at most rearrangement junctions indicate that these have been mediated by non-homologous end-joining DNA repair, although varying sequence patterns indicate that multiple processes of this type are operative. Several expressed in-frame fusion genes were identified but none was recurrent. The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development.

1 September 2010 in Cell Stem Cell
Verified
Journal Article
Closed access
GMGemma Molyneux
Gemma Molyneux
FGFelipe C. Geyer
Felipe C. Geyer
FMFiona-Ann Magnay
Fiona-Ann Magnay
AMAfshan McCarthy
Afshan McCarthy
HKHoward Kendrick
Howard Kendrick
MSMatthew J. Smalley
Matthew J. Smalley

28 February 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NTNicholas Turner
Nicholas Turner
APAlex Pearson
Alex Pearson
RSRachel Sharpe
Rachel Sharpe
MLMaryou Lambros
Maryou Lambros
FGFelipe Geyer
Felipe Geyer
AAAlan Ashworth
Alan Ashworth
Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ∼10% of breast cancers and is associated with poor prognosis. However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers. Here, we show that FGFR1 overexpression is robustly associated with FGFR1 amplification in two independent series of breast cancers. Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase–AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth. FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance. FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR negative, identifying a potential biomarker for FGFR1 activity. Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B–type breast cancers. Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance. Cancer Res; 70(5); 2085–94

18 January 2010 in Oncogene
Verified
Journal Article
Open access
PDF file
NTN Turner
N Turner
MLM B Lambros
M B Lambros
HHH M Horlings
H M Horlings
APA Pearson
A Pearson
RSR Sharpe
R Sharpe
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Triple negative breast cancers (TNBCs) have a relatively poor prognosis and cannot be effectively treated with current targeted therapies. We searched for genes that have the potential to be therapeutic targets by identifying genes consistently overexpressed when amplified. Fifty-six TNBCs were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH), of which 24 were subjected to genome-wide gene expression analysis. TNBCs were genetically heterogeneous; no individual focal amplification was present at high frequency, although 78.6% of TNBCs harboured at least one focal amplification. Integration of aCGH and expression data revealed 40 genes significantly overexpressed when amplified, including the known oncogenes and potential therapeutic targets, FGFR2 (10q26.3), BUB3 (10q26.3), RAB20 (13q34), PKN1 (19p13.12) and NOTCH3 (19p13.12). We identified two TNBC cell lines with FGFR2 amplification, which both had constitutive activation of FGFR2. Amplified cell lines were highly sensitive to FGFR inhibitor PD173074, and to RNAi silencing of FGFR2. Treatment with PD173074 induced apoptosis resulting partly from inhibition of PI3K-AKT signalling. Independent validation using publicly available aCGH data sets revealed FGFR2 gene was amplified in 4% (6/165) of TNBC, but not in other subtypes (0/214, P=0.0065). Our analysis demonstrates that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours.

31 August 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MTMunir R. Tanas
Munir R. Tanas
ASAndrea Sboner
Andrea Sboner
AOAndre M. Oliveira
Andre M. Oliveira
MEMichele R. Erickson-Johnson
Michele R. Erickson-Johnson
JHJessica Hespelt
Jessica Hespelt
BRBrian P. Rubin
Brian P. Rubin
Integrating transcriptomic sequencing with conventional cytogenetics, we identified WWTR1 (WW domain–containing transcription regulator 1) (3q25) and CAMTA1 (calmodulin-binding transcription activator 1) (1p36) as the two genes involved in the t(1;3)(p36;q25) chromosomal translocation that is characteristic of epithelioid hemangioendothelioma (EHE), a vascular sarcoma. This WWTR1/CAMTA1 gene fusion is under the transcriptional control of the WWTR1 promoter and encodes a putative chimeric transcription factor that joins the amino terminus of WWTR1, a protein that is highly expressed in endothelial cells, in-frame to the carboxyl terminus of CAMTA1, a protein that is normally expressed only in brain. Thus, CAMTA1 expression is activated inappropriately through a promoter-switch mechanism. The gene fusion is present in virtually all EHEs tested but is absent from all other vascular neoplasms, demonstrating it to be a disease-defining genetic alteration. A sensitive and specific break-apart fluorescence in situ hybridization assay was also developed to detect the translocation and will assist in the evaluation of this diagnostically challenging neoplasm. The chimeric WWTR1/CAMTA1 transcription factor may represent a therapeutic target for EHE and offers the opportunity to shed light on the functions of two poorly characterized proteins.